Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (695)	7/30/1998 5:14:00 PM
From: Vector1	Read Replies (1) \| Respond to of 3202

<<I am also thrilled to see INCY taking equity for intellectual property. Even though it isn't for genomic services, it is a good start. I've suggested for years that INCY consider taking equity in smaller biotechs in return for their genomic services, but management has never been in favor of it. I'd love to see INCY hold a big portfolio of equity, warrants, or options in lots of other biotechs. In my mind it is a great way to diversify their financials and greatly expand the number of users of their services. >> YES. I couldn't agree more. Gee getting equity in exchange for their intellectual propery is just another form of royalty. We have discussed this before but INCY could make portions of theri database available to midsized biotechs in exchange for warrants or downstream royalties. They have the intellectual property. Exploit it to its fullest. Also what is INCY doing on the funtional genomics side. Being able to tie the gene to funtion would create multiples of the value of the gene itself. V1 V1